Sanofi $SNY Shares Sold by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. cut its holdings in shares of Sanofi (NASDAQ:SNY) by 19.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 55,120 shares of the company’s stock after selling 13,513 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Sanofi were worth $2,671,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SNY. Flagship Harbor Advisors LLC acquired a new position in shares of Sanofi in the fourth quarter worth about $25,000. Financial Consulate Inc. acquired a new position in shares of Sanofi in the third quarter worth about $26,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Sanofi in the third quarter worth about $29,000. Palisade Asset Management LLC acquired a new position in shares of Sanofi in the third quarter worth about $30,000. Finally, First Horizon Corp acquired a new position in shares of Sanofi in the third quarter worth about $33,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Up 1.3%

SNY opened at $47.53 on Friday. Sanofi has a twelve month low of $43.32 and a twelve month high of $55.73. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The company has a 50-day moving average price of $46.40 and a 200 day moving average price of $48.00. The company has a market cap of $115.93 billion, a PE ratio of 13.20, a price-to-earnings-growth ratio of 1.17 and a beta of 0.42.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Wednesday, June 3rd. Investors of record on Monday, May 4th will be given a dividend of $2.4225 per share. This is a boost from Sanofi’s previous annual dividend of $2.04. The ex-dividend date is Monday, May 4th. This represents a dividend yield of 502.0%. Sanofi’s payout ratio is currently 44.44%.

More Sanofi News

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi beat Q1 earnings and revenue estimates, with strong Dupixent sales and new-product contributions supporting double-digit growth and reaffirming its 2026 outlook. Sanofi Tops Q1 Earnings Estimates as Dupixent & New Drugs Drive Growth
• Positive Sentiment: Dupixent (with Regeneron) received FDA approval as the first biologic for children ages 2–11 with uncontrolled chronic spontaneous urticaria (CSU), expanding the drug’s pediatric label and supporting long-term sales growth. Sanofi and Regeneron’s Dupixent becomes first biologic for kids under 12 with CSU
• Positive Sentiment: Tzield’s FDA supplemental approval expands use to much younger children (as young as one year) to delay onset of stage 3 type 1 diabetes, creating a new disease-modifying pediatric indication and increasing peak sales potential. Sanofi’s Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
• Neutral Sentiment: Management/leadership transition noted in coverage — sales momentum remains but investors may watch the handover for strategic signals. Sanofi Posts Higher Sales Amid Leadership Transition
• Negative Sentiment: The FDA extended the review (up to three months) for the Sarclisa (isatuximab) subcutaneous BLA, delaying a potential commercial launch that could have boosted multiple myeloma sales sooner; a new FDA decision date is now set for July 2026. Press-Release-Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

Analysts Set New Price Targets

SNY has been the subject of a number of analyst reports. UBS Group reiterated a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Barclays downgraded shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Citigroup reiterated a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Weiss Ratings upgraded shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, April 9th. Finally, Wall Street Zen downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $54.00.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.